LU92939I2 - Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable - Google Patents
Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable Download PDFInfo
- Publication number
- LU92939I2 LU92939I2 LU92939C LU92939C LU92939I2 LU 92939 I2 LU92939 I2 LU 92939I2 LU 92939 C LU92939 C LU 92939C LU 92939 C LU92939 C LU 92939C LU 92939 I2 LU92939 I2 LU 92939I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- isavuconazonium
- salt
- isavuconbazole
- sulphate
- hydrate
- Prior art date
Links
- RSWOJTICKMKTER-QXLBVTBOSA-N isavuconazonium Chemical compound CNCC(=O)OCC1=CC=CN=C1N(C)C(=O)OC(C)[N+]1=CN(C[C@@](O)([C@@H](C)C=2SC=C(N=2)C=2C=CC(=CC=2)C#N)C=2C(=CC=C(F)C=2)F)N=C1 RSWOJTICKMKTER-QXLBVTBOSA-N 0.000 title 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title 1
- 150000001450 anions Chemical class 0.000 title 1
- 229960004922 isavuconazonium Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 229910021653 sulphate ion Inorganic materials 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99121694 | 1999-11-02 | ||
| EP00992946A EP1280795B1 (en) | 1999-11-02 | 2000-10-25 | N-substituted carbamoyloxyalkyl-azolium derivatives |
| PCT/EP2000/010524 WO2001032652A2 (en) | 1999-11-02 | 2000-10-25 | N-substituted carbamoyloxyalkyl-azolium derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92939I2 true LU92939I2 (fr) | 2016-03-07 |
Family
ID=8239312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92939C LU92939I2 (fr) | 1999-11-02 | 2016-01-06 | Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1280795B1 (en]) |
| JP (1) | JP3787307B2 (en]) |
| KR (1) | KR100449797B1 (en]) |
| CN (1) | CN1185230C (en]) |
| AR (1) | AR029403A1 (en]) |
| AT (1) | ATE291575T1 (en]) |
| AU (1) | AU777859B2 (en]) |
| BE (1) | BE2016C007I2 (en]) |
| BR (1) | BRPI0015254C1 (en]) |
| CA (2) | CA2680292C (en]) |
| CY (1) | CY2016002I2 (en]) |
| DE (1) | DE60018989T2 (en]) |
| DK (1) | DK1280795T3 (en]) |
| ES (1) | ES2238341T3 (en]) |
| FR (1) | FR15C0096I2 (en]) |
| LU (1) | LU92939I2 (en]) |
| MX (1) | MXPA02004145A (en]) |
| NL (1) | NL300791I1 (en]) |
| PT (1) | PT1280795E (en]) |
| TR (1) | TR200201205T2 (en]) |
| WO (1) | WO2001032652A2 (en]) |
| ZA (1) | ZA200203003B (en]) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| PL2192893T3 (pl) | 2007-08-21 | 2015-12-31 | Basilea Pharmaceutica Ag | Kompozycja przeciwgrzybicza |
| US9907812B2 (en) | 2011-06-22 | 2018-03-06 | Vyome Biosciences Pvt. Ltd. | Conjugate-based antifungal and antibacterial prodrugs |
| MX2015016675A (es) | 2013-06-04 | 2016-07-15 | Vyome Biosciences Pvt Ltd | Particulas recubiertas y composiciones que comprenden las mismas. |
| CN104230894B (zh) * | 2013-06-06 | 2016-08-24 | 南京华威医药科技开发有限公司 | 三唑类化合物 |
| CN107207414B (zh) | 2014-12-30 | 2021-03-30 | 美国陶氏益农公司 | 具有杀真菌活性的吡啶酰胺化合物 |
| CN106032356B (zh) * | 2015-03-13 | 2018-09-14 | 江苏正大丰海制药有限公司 | 一种[n-甲基-吡啶-2-基]氨基甲酸-1-氯乙酯的制备方法 |
| CN104974143A (zh) * | 2015-05-12 | 2015-10-14 | 深圳致君制药有限公司 | 一种季铵盐类化合物、其制备方法以及用途 |
| CN106467519B (zh) * | 2015-08-17 | 2019-08-13 | 南京华威医药科技集团有限公司 | 一种水溶性三唑化合物 |
| CN106467534B (zh) * | 2015-08-17 | 2019-10-11 | 江苏奥赛康药业有限公司 | 一种硫酸艾沙康唑鎓化合物及其药物组合物 |
| CN106565699B (zh) * | 2015-10-10 | 2019-07-26 | 江苏正大丰海制药有限公司 | 一种艾沙康唑硫酸盐晶体及其制备方法 |
| US10683387B2 (en) | 2016-10-04 | 2020-06-16 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
| US11040958B2 (en) | 2017-02-17 | 2021-06-22 | Wuhan Ll Science And Technology Development Co., Ltd. | Triazole antimicrobial derivative, pharmaceutical composition and use thereof |
| CN106916152B (zh) * | 2017-04-27 | 2019-09-17 | 扬子江药业集团有限公司 | 氧化还原反应制备艾沙康唑鎓单硫酸盐的方法 |
| US10716858B2 (en) | 2017-06-30 | 2020-07-21 | Massachusetts Institute Of Technology | Branched multi-functional macromonomers and uses thereof |
| US11752221B2 (en) | 2017-06-30 | 2023-09-12 | Massachusetts Institute Of Technology | Brush-arm star polymer imaging agents and uses thereof |
| US10368502B2 (en) | 2017-09-25 | 2019-08-06 | Multiple Energy Technologies Llc | Bioceramic and carbon-based hydroponic systems, methods and devices |
| CN110317165A (zh) * | 2018-03-28 | 2019-10-11 | 上海医药工业研究院 | 一种药物中间体2-甲胺基-3-吡啶甲醇的制备方法 |
| CN110551064B (zh) * | 2018-06-01 | 2021-01-01 | 重庆世森医药科技有限公司 | 艾沙康唑硫酸酯及其中间体的制备方法 |
| JP7433288B2 (ja) | 2018-08-01 | 2024-02-19 | バジリア・ファルマスーチカ・インターナショナル・アーゲー，アルシュヴィル | イサブコナゾニウム硫酸塩を精製するための方法 |
| EP3837266A1 (en) | 2018-08-17 | 2021-06-23 | Massachusetts Institute of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| CN110128420A (zh) * | 2019-05-08 | 2019-08-16 | 阴启明 | 硫酸氢根/硫酸根型阴离子交换技术制备艾沙康唑鎓单硫酸盐的方法 |
| WO2021037597A1 (en) | 2019-08-26 | 2021-03-04 | Synthon B.V. | Isavuconazonium salts and process for preparing thereof |
| AU2020368453A1 (en) * | 2019-10-16 | 2022-04-21 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
| US12042513B2 (en) | 2020-01-10 | 2024-07-23 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof |
| JP7454905B2 (ja) * | 2021-09-28 | 2024-03-25 | 旭化成ファーマ株式会社 | 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び／又は予防剤 |
| JP7570382B2 (ja) | 2021-09-28 | 2024-10-21 | 旭化成ファーマ株式会社 | エアベント付き輸液フィルタを備える点滴静脈投与用輸液セット |
| US12084415B2 (en) | 2021-12-20 | 2024-09-10 | Massachusetts Institute Of Technology | Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent |
| EP4289840A1 (en) | 2022-06-07 | 2023-12-13 | Zaklady Farmaceutyczne Polpharma S.A. | A process for preparing isavuconazonium sulfate |
| WO2024094329A1 (en) | 2022-11-01 | 2024-05-10 | Basilea Pharmaceutica International Ag, Allschwil | Blister-packaged capsule preparation containing isavuconazonium sulfate |
| WO2024189550A1 (en) * | 2023-03-13 | 2024-09-19 | Apitoria Pharma Private Limited | Process for the preparation of isavuconazonium sulfate and its crystalline forms |
| WO2025114603A1 (en) | 2023-11-30 | 2025-06-05 | Basilea Pharmaceutica International Ag, Allschwil | Pharmaceutical combinations for use in the treatment of fungal infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3108997B2 (ja) * | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
| KR20010005792A (ko) * | 1997-03-31 | 2001-01-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 아졸 화합물, 이의 제조 방법 및 용도 |
| WO1999045008A1 (en) * | 1998-03-06 | 1999-09-10 | F. Hoffmann-La Roche Ag | 3-[4-(4-cyanophenyl)thiazol-2-y)]-1-(1h-1,2,4-triazol-1-yl)-butan-2-ol derivatives having antifungal activity |
-
2000
- 2000-10-25 AU AU28352/01A patent/AU777859B2/en active Active
- 2000-10-25 MX MXPA02004145A patent/MXPA02004145A/es active IP Right Grant
- 2000-10-25 CN CNB008153299A patent/CN1185230C/zh not_active Expired - Lifetime
- 2000-10-25 PT PT00992946T patent/PT1280795E/pt unknown
- 2000-10-25 JP JP2001534803A patent/JP3787307B2/ja not_active Expired - Lifetime
- 2000-10-25 DK DK00992946T patent/DK1280795T3/da active
- 2000-10-25 CA CA2680292A patent/CA2680292C/en not_active Expired - Lifetime
- 2000-10-25 DE DE60018989T patent/DE60018989T2/de not_active Expired - Lifetime
- 2000-10-25 BR BRPI0015254A patent/BRPI0015254C1/pt not_active IP Right Cessation
- 2000-10-25 AT AT00992946T patent/ATE291575T1/de active
- 2000-10-25 CA CA002388320A patent/CA2388320C/en not_active Expired - Lifetime
- 2000-10-25 TR TR2002/01205T patent/TR200201205T2/xx unknown
- 2000-10-25 EP EP00992946A patent/EP1280795B1/en not_active Expired - Lifetime
- 2000-10-25 WO PCT/EP2000/010524 patent/WO2001032652A2/en active Search and Examination
- 2000-10-25 KR KR10-2002-7005574A patent/KR100449797B1/ko not_active Expired - Lifetime
- 2000-10-25 ES ES00992946T patent/ES2238341T3/es not_active Expired - Lifetime
- 2000-10-31 AR ARP000105739A patent/AR029403A1/es active IP Right Grant
-
2002
- 2002-04-16 ZA ZA200203003A patent/ZA200203003B/xx unknown
-
2015
- 2015-12-29 FR FR15C0096C patent/FR15C0096I2/fr active Active
-
2016
- 2016-01-06 LU LU92939C patent/LU92939I2/xx unknown
- 2016-01-26 NL NL300791C patent/NL300791I1/nl unknown
- 2016-02-03 CY CY2016002C patent/CY2016002I2/el unknown
- 2016-02-26 BE BE2016C007C patent/BE2016C007I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92939I2 (fr) | Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable | |
| LU91681I2 (fr) | "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)" | |
| NO2020019I1 (no) | Maraviroc eventuelt i form av et farmasøytisk akseptabelt salt | |
| LU91372I2 (fr) | Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo) | |
| LU91442I2 (fr) | "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate" | |
| LU88842I2 (fr) | Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol | |
| LU92428I2 (fr) | Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable | |
| LU92397I2 (fr) | Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable | |
| NL990028I1 (nl) | Abacavir, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of derivaat, in het bijzonder abacavir sulfaat. | |
| MA26641A1 (fr) | Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments | |
| NO20013953L (no) | Dreibart kontrollhode innvendig i stigerör | |
| IS1812B (is) | Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra | |
| LU91027I2 (fr) | Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable | |
| LU90468I2 (fr) | Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable | |
| HUP0302553A3 (en) | Salts of a isothiazole-4-carboxamide and process for their preparation and use for the preparation of anti-hyperproliferation agents | |
| IS6376A (is) | Heterósýkló-alkýlsúlfónýl pýrazól afleiður sem bólgueyðandi/kvalastillandi miðlar | |
| EP1293131A4 (en) | MEANS FOR CLEANING TREATMENT | |
| HUP0102946A3 (en) | Composition comprising at least one uv screening agent and a flavynium salt which is unsubstituted in position 3, for colouring the skin and use its | |
| EP1274431A4 (en) | 10,11-DIFLUOROMETHYLENE DIOXYCAMTOTHECINE COMPOUNDS WITH TOPOISOMERASE-I INHIBITION | |
| FR2854795B1 (fr) | Composition cosmetique visant a creer une variation de couleur avec l'angle d'observation | |
| IL165851A0 (en) | The use of benziselenazolone compounds in the preparation of medicament against ischemic myocardial injury | |
| IL152061A0 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| GB9921537D0 (en) | The ultimate rig | |
| NL300094I1 (nl) | Combinatie van budeonide en formoterol, desgewenstin de vorm van een farmaceutisch aanvaardbaar zou t, ester en/of hydraat. | |
| Fraser | Showstopper. |